Last reviewed · How we verify
P.O cefuroxime 500 mgx2/d for 5 days
P.O cefuroxime 500 mgx2/d for 5 days is a Second-generation cephalosporin Small molecule drug developed by Western Galilee Hospital-Nahariya. It is currently FDA-approved for Bacterial respiratory tract infections, Urinary tract infections, Skin and soft tissue infections.
Cefuroxime is a second-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins.
Cefuroxime is a second-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. Used for Bacterial infections including respiratory tract infections, urinary tract infections, skin and soft tissue infections, and Lyme disease, Perioperative prophylaxis in surgical procedures.
At a glance
| Generic name | P.O cefuroxime 500 mgx2/d for 5 days |
|---|---|
| Sponsor | Western Galilee Hospital-Nahariya |
| Drug class | Second-generation cephalosporin |
| Target | Penicillin-binding proteins (PBPs) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Cefuroxime works by disrupting the cross-linking of peptidoglycan in the bacterial cell wall, leading to cell wall instability and bacterial death. It has broad-spectrum activity against both gram-positive and gram-negative bacteria, making it effective against a wide range of infections. The oral formulation (P.O.) is well-absorbed and achieves therapeutic concentrations in most body tissues.
Approved indications
- Bacterial respiratory tract infections
- Urinary tract infections
- Skin and soft tissue infections
- Lyme disease
- Other susceptible bacterial infections
Common side effects
- Diarrhea
- Nausea
- Headache
- Vomiting
- Hypersensitivity reactions
- Abdominal pain
Key clinical trials
- Comparison of Two Antibiotic Prophylactic Protocols in Preterm Premature Rupture of the Membranes (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- P.O cefuroxime 500 mgx2/d for 5 days CI brief — competitive landscape report
- P.O cefuroxime 500 mgx2/d for 5 days updates RSS · CI watch RSS
- Western Galilee Hospital-Nahariya portfolio CI
Frequently asked questions about P.O cefuroxime 500 mgx2/d for 5 days
What is P.O cefuroxime 500 mgx2/d for 5 days?
How does P.O cefuroxime 500 mgx2/d for 5 days work?
What is P.O cefuroxime 500 mgx2/d for 5 days used for?
Who makes P.O cefuroxime 500 mgx2/d for 5 days?
What drug class is P.O cefuroxime 500 mgx2/d for 5 days in?
What development phase is P.O cefuroxime 500 mgx2/d for 5 days in?
What are the side effects of P.O cefuroxime 500 mgx2/d for 5 days?
What does P.O cefuroxime 500 mgx2/d for 5 days target?
Related
- Drug class: All Second-generation cephalosporin drugs
- Target: All drugs targeting Penicillin-binding proteins (PBPs)
- Manufacturer: Western Galilee Hospital-Nahariya — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for Bacterial respiratory tract infections
- Indication: Drugs for Urinary tract infections
- Indication: Drugs for Skin and soft tissue infections
- Compare: P.O cefuroxime 500 mgx2/d for 5 days vs similar drugs
- Pricing: P.O cefuroxime 500 mgx2/d for 5 days cost, discount & access